PubMed Health⌕ Search

Biomedical subjects

B R Harrison

Publications and source records attributed to B R Harrison.

12 recordsLinked to original sources
PubMed1996

Quality-assurance testing of staff pharmacists handling cytotoxic agents.

Competency-based simulation testing was used to improve staff pharmacists' handling of cytotoxic agents. Pharmacists were asked to prepare a simulated liquid cytotoxic agent (fluorescein sodium 0.5 mg/ml.) according to the pharmacy service standard operating procedures. Participants were observed throughout the preparation to assess proper safety and aseptic technique, waste disposal, and labeling. Ultraviolet light was used to assess surface contamination. After the test, errors were discussed with each participant. All participants then received scheduled annual training on preparation of cytotoxic agents, and they took the simulation test again three months later. Thirteen staff members completed all testing. Simulation test scores improved from 61% to 84%. Evidence of surface contamination was found for 92% of these pharmacists during the pretest and only 23% during the posttest. Written test scores improved, but not significantly, from 85% to 89%. Each simulation and feedback session took 30 minutes. Simulation testing significantly improved competence in preparation of cytotoxic agents.

Antineoplastic Agents↗
PubMed1996

Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.

Systemic fungal infections (SFI) in patients receiving high-dose chemotherapy (HDC) are a frequent cause of morbidity and mortality. Preclinical studies have reported augmented antifungal activity of monocytes, macrophage cells, and neutrophils exposed to certain colony-stimulating factors (CSF), including GM-CSF. We conducted a retrospective descriptive epidemiologic study to examine the characteristics of 145 consecutive patients receiving HDC administered with or without autologous stem cell transplantation (ASCT) and who subsequently received either GM-CSF and G-CSF, G-CSF alone, GM-CSF +/- IL-3 or no CSF. The analysis of this patient population sought to define the incidence of SFI and its relationship to therapy with monocyte/macrophage-stimulating (MMS group) cytokines (GM-CSF and G-CSF; GM-CSF +/- IL-3) or to cytokines which do not result in monocyte/macrophage stimulation (NMMS group, G-CSF alone or no CSF). Risk factors for the development of SFI were balanced between the MMS (n = 70) and NMMS (n = 75) groups. Two patients (2.9%) in the MMS and nine patients (12%) in the NMMS groups developed SFI. The risk ratio for developing SFI in the NMMS group compared to the MMS group was 4.20 (P = 0.023). This relationship was confounded, however, by the diagnosis of hematologic tumor or solid tumor (RR = 3.15, P = 0.082). SFI was the primary cause or major contributing factor in five of the 10 total deaths in our study population. Four SFI-related deaths occurred in the NMMS group and one SFI-related death occurred in the MMS group. Our data suggest a protective role for GM-CSF, IL-3 or other MMS cytokines in preventing SFI in patients receiving HDC. This should be further investigated as a potential complementary approach to conventional strategies in antifungal prophylaxis for patients receiving HDC.

Adult↗
PubMed1993

IR-192, low dose rate endobronchial brachytherapy in the treatment of malignant airway obstruction.

PURPOSE: To assess the value of low-dose-rate endobronchial brachytherapy in the treatment of malignant airway obstruction. METHODS AND MATERIALS: Between September 1986 and April 1989, 39 patients with malignant airway obstruction had 49 catheter placements for an afterloading, low-dose-rate Ir-192 endobronchial brachytherapy. A flexible fiberoptic bronchoscope with fluoroscopic guidance was used for positioning. Thirty-eight of 39 (97%) patients completed the prescribed treatments. Ninety-seven percent had received previous external radiation in doses ranging from 36-60 Gy. One patient had metastatic renal cell carcinoma; the remainder had recurrent lung cancer. Endobronchial laser treatments were given to three patients 2-3 weeks prior to endobronchial brachytherapy. All patients were followed until death. The median dose delivered in 48 of the 49 placements was 20 Gy at 1 cm. RESULTS: Follow-up bronchoscopy was performed in 28 (72%) of 39 patients. Of these, 13 (46%) had a complete response, 12 (43%) had a partial response, and 3 (17%) had a minor response. Dyspnea improved in 30 of 37 patients (82%); hemoptysis in 17 of 19 patients (89%); cough in 31 of 39 patients (79%); and postobstructive pneumonia in 21 of 23 patients (92%). The median survival for the entire group was 5 months (range 1-31 months). CONCLUSION: This technique is simple, well-tolerated and offered significant palliation.

Adult↗
PubMed1991

Chemo-irradiation induced aortoesophageal fistula.

A patient with squamous cell carcinoma of the esophagus developed fatal aortoesophageal (AE) fistula following a preoperative course of combined chemotherapy plus radiation therapy. This is the first reported case of AE fistula following preoperative chemoradiotherapy. This complication is potentially correctable if suspected early, since the massive hemorrhage characteristic of AE fistula is usually preceded by an initial sentinel hemorrhage. The cause of this complication is not clear, but it may be due to inflammation of the vasa vasorum with necrosis of the aortic wall. The concomitant use of fluorouracil and cisplatin with radiation therapy acts as a radiosensitizer and may have potentiated the radiation effect on the aortic wall.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin.

Two of 33 patients entered in a local pilot study of mitomycin, vinblastine, and cisplatin for non-small cell lung cancer developed vinblastine-associated pulmonary toxicity. As with other reports of vinca alkaloid-related pulmonary toxicity, the regimen included mitomycin. Based on these cases and others previously reported, the incidence of abrupt pulmonary toxicity following vinca alkaloid administration as part of mitomycin/vinca alkaloid combination appears to be three to six percent. Suggestions for management are given.

Adenocarcinoma↗
PubMed1986

Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma.

Dacarbazine has shown the most consistent activity of any single chemotherapeutic agent in patients with metastatic melanoma. While the overall rate is 21%, responses fall to less than 10% when hepatic metastases are present. We report a patient with malignant melanoma metastatic to the liver in whom an apparent dose-response relationship to dacarbazine was demonstrated. His liver metastases responded to hepatic artery infusion, progressed with systemic iv therapy, and responded upon reinstitution of hepatic artery infusion.

Dacarbazine↗
PubMed1984

Lack of effect of vitamin E therapy on the anemia of patients receiving hemodialysis.

We conducted a prospective, randomized, double-blind therapeutic trial of vitamin E as an erythropoietic agent in a group of patients with chronic renal failure who were undergoing chronic hemodialysis. Sixteen patients received 400 IU of vitamin E (d-alpha-tocopheryl acetate) by mouth twice daily and 19 patients received a placebo twice daily for 20 wk. The serum vitamin E concentration increased from 1.3 to 2.6 mg/dl in the treated group and decreased from 1.3 to 1.1 in the placebo group. For the treated group the initial hematocrit was 24.8 +/- 3.0 (mean +/- SD) and the final hematocrit was 25.8 +/- 3.8. For the placebo group the initial hematocrit was 24.9 +/- 3.0 and the final hematocrit was 23.5 +/- 2.7. The treated group received a total of 40 blood transfusions, and the placebo group received a total of 35 blood transfusions. Thus, vitamin E had no effect on the anemia or transfusion requirements of patients undergoing chronic hemodialysis for chronic renal failure.

Anemia↗
PubMed1981

Developing guidelines for working with antineoplastic drugs.

The potentially hazardous properties of antineoplastic drugs and problems associated with the admixture and administration of injectable antineoplastics are reviewed. The mutagenicity of anticancer drugs, carcinogenicity testing in animals, carcinogenicity of antineoplastic agents in humans, and federal regulation of carcinogens are discussed. Concern in the literature regarding the handling of antineoplastic drugs in reviewed briefly, and guidelines for proper handling are suggested. Local hospital guidelines on the handling of antineoplastic drug products should be designed to protect health-care workers from unnecessary exposure to potential carcinogens.

Antineoplastic Agents↗
PubMed1979

Coombs'-positive hemolytic anemia and ibuprofen.

A patient who developed an autoimmune hemolytic anemia during treatment with ibuprofen (Motrin) is described. Positive indirect Coombs' reaction was demonstrated with the patient's red blood cell eluate in the presence of the drug, supporting a drug-related immune hemolysis. The positive direct Coombs' reaction to anti-C3 antiserum strongly suggested that the immune hemolysis in this patient is probably mediated through complement alone; however, the presence of a small amount of IgG antibodies on the surface of the red blood cells which cannot be detected under conventional screening procedures cannot be completely excluded. Further studies, both clinical and laboratory, disclosed that the responsible ingredient in this particular instance appeared to be the orange dye coating of the Motrin-400 tablet rather than the ibuprofen itself.

Aged↗